시장보고서

상품코드

1654223

광선각화증 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료법별, 약제 클래스별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (NSAIDs), By End use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 01월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

광선각화증 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 광선각화증 치료 시장 규모는 2025-2030년에 CAGR 4.1%를 기록하며, 2030년까지 89억 3,000만 달러에 달할 전망입니다.

광선각화증 치료제의 광범위한 가용성, 질환에 대한 인식 증가, AK 치료 증가 등의 요인으로 인해 광선각화증 치료제 시장은 성장 기회를 맞이할 것으로 예상됩니다. 또한 광선각화증의 유병률 증가와 전 세계 노인 인구 증가는 예측 기간 중 시장 성장을 가속할 것으로 예상됩니다.

침윤성 편평상피암은 AK에서 악성화(iSCC)되면 발생할 수 있으며, iSCC의 잠재적 원인은 여러 가지가 있지만, AK가 가장 흔한 원인 중 하나입니다. 또한 기저세포암과 비흑색종 피부암도 AK에서 발생할 수 있습니다. 그 결과, 판매 채널을 막론하고 광선각화증의 조기 진단과 치료는 합병증 예방 전략으로 AK 제품에 대한 수요의 원동력이 되고 있습니다.

또한 향후 파이프라인 의약품과 병용요법 증가가 시장 성장 촉진요인으로 작용하고 있습니다. 예를 들어 Almirall, S.A.는 임상 3상 단계에 있는 Klisyri(적응증 확대)를 보유하고 있습니다. 또한 혁신적인 의약품이 수용되어 상품화되는 것도 시장 성장을 가속하는 요인 중 하나로 예측됩니다. 또한 연구개발 활동이 활발해짐에 따라 광선각화증 치료에 사용되는 새로운 약물의 승인이 가속화될 것으로 예상에 따라 예측 기간 중 성장을 가속할 것으로 예상됩니다.

주요 기업은 전 세계 시장 점유율을 확대하기 위해 제품 출시, 제휴, 확장 전략과 같은 전략적 구상을 채택하고 있습니다. 예를 들어 2022년 6월 바이오프론테라(BIOFRONTERA AG)는 스위스에 본사를 둔 루이 위드머(Louis Widmer SA)가 아멜루즈(Ameluz)의 체간, 사지, 경부 광선각화증 치료제로 판매 승인을 연장 받았다고 발표했습니다. 또한 BIOFRONTERA AG는 2020년 7월 Galenica AB와 노르웨이, 핀란드, 노르웨이, 아이슬란드에서 BF-RhodoLED 및 Ameluz의 판매 계약을 체결했다고 발표했습니다.

광선각화증 치료 시장 보고서 하이라이트:

광선각화증 관리에서 냉동요법 수술의 채택이 증가함에 따라 2024년에는 수술이 63.8%의 가장 큰 매출 점유율을 차지했습니다.
뉴클레오시드 대사 억제제는 2024년 가장 큰 매출 점유율을 차지하며, 예측 기간 중에도 그 우위를 유지할 것으로 예상됩니다.
아시아태평양은 높은 AK 유병률, 빠르게 발전하는 의료 인프라, 아시아태평양 국가의 의료비 증가 등의 요인으로 인해 예측 기간 중 CAGR 5.4%로 가장 빠른 속도로 성장할 것으로 예상됩니다.
북미는 광선각화증에 대한 인식 증가, 다양한 치료 옵션의 가용성, 의료 인프라 개선 등으로 2024년 40.5%의 가장 큰 매출 점유율을 차지하며 시장을 독점했습니다.

지역의 시장 점유율 분석, 2024년 및 2030년
지역의 시장 대시보드
시장 규모와 예측 동향 분석, 2018-2030년 :
북미
- 국가별
- 미국
- 캐나다
유럽
- 국가별
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
라틴아메리카
- 국가별
- 브라질
- 멕시코
- 아르헨티나
중동 및 아프리카
- 국가별
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트

제8장 경쟁 구도

참가자 개요
기업의 시장 현황 분석
기업 분류
전략 지도제작
기업 개요/상장기업
- Almirall, SA
- LEO Pharma A/S
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Galderma
- Ortho Dermatologics(Bausch Health Companies Inc.)
- BIOFRONTERA Inc
- Hill Dermaceuticals, Inc
- 3M
- Alma Lasers

KSA 25.03.13

Actinic Keratosis Treatment Market Growth & Trends:

The global actinic keratosis treatment market size is expected to reach USD 8.93 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, and Iceland.

Actinic Keratosis Treatment Market Report Highlights:

Surgery held the largest revenue share of 63.8% in 2024 owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis
Nucleoside metabolic inhibitors held the largest revenue share in 2024 and is expected to retain its dominance over the forecast period
Asia Pacific is expected to grow at the fastest CAGR of 5.4% during the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries
North America dominated the market with the largest revenue share of 40.5% in 2024 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Therapy
- 1.2.2. Drug Class
- 1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Actinic Keratosis Treatment Market: Therapy Business Analysis

4.1. Therapy Market Share, 2024 & 2030
4.2. Therapy Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
4.4. Topical
- 4.4.1. Topical Market, 2018 - 2030 (USD Million)
4.5. Surgery
- 4.5.1. Surgery Market, 2018 - 2030 (USD Million)
4.6. Photodynamic Therapy
- 4.6.1. Photodynamic Therapy Market, 2018 - 2030 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Business Analysis

5.1. Drug Class Market Share, 2024 & 2030
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Nucleoside Metabolic Inhibitor
- 5.4.1. Nucleoside Metabolic Inhibitor Market, 2018 - 2030 (USD Million)
5.5. NSAIDs
- 5.5.1. NSAIDs Market, 2018 - 2030 (USD Million)
5.6. Immune Response Modifiers
- 5.6.1. Immune Response Modifiers Market, 2018 - 2030 (USD Million)
5.7. Photoenhancers
- 5.7.1. Photoenhancers Market, 2018 - 2030 (USD Million)
5.8. Others
- 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End Use Business Analysis

6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
- 6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
6.5. Private Clinics
- 6.5.1. Private Clinics Market, 2018 - 2030 (USD Million)
6.6. Homecare
- 6.6.1. Homecare Market, 2018 - 2030 (USD Million)
6.7. Others
- 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Japan Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. China Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. South Korea Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. Australia Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Mexico
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Mexico Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. Argentina
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Regulatory Framework
  - 7.7.4.3. Competitive Insights
  - 7.7.4.4. Argentina Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
- 7.8.1. MEA Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Almirall, S.A
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. LEO Pharma A/S
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Sun Pharmaceutical Industries Ltd.
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Novartis AG
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Galderma
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Ortho Dermatologics (Bausch Health Companies Inc.)
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. BIOFRONTERA Inc
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Hill Dermaceuticals, Inc
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. 3M
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Alma Lasers
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives

광선각화증 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료법별, 약제 클래스별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (NSAIDs), By End use, By Region, And Segment Forecasts, 2025 - 2030

광선각화증 치료 시장의 성장과 동향 :

광선각화증 치료 시장 보고서 하이라이트:

목차

제1장 조사 방법과 범위

제2장 개요

제3장 광선각화증 치료 시장의 변수, 동향, 범위

제4장 광선각화증 치료 시장 : 치료법 비즈니스 분석

제5장 광선각화증 치료 시장 : 약물 클래스 비즈니스 분석

제6장 광선각화증 치료 시장 : 최종 용도의 비즈니스 분석

제7장 광선각화증 치료 시장 : 지역의 추정·동향 분석